Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Generic Drugs Launches Legal Issues

Cipla, Piramal Launch Sensipar Generics Amid Growing Antitrust Challenges to Amgen/Teva Settlement

  • Analysis

Executive Summary

Amgen seeks a preliminary injunction to halt US sales by Cipla and says it will take steps to stop Piramal’s sales; in its antitrust lawsuit, Cipla alleges Amgen paid to license Teva products under the companies’ patent settlement, which resulted in Teva pulling its generic off the market shortly after launch.


Table

View full table

Advertisement

Related Content

Generics Bulletin
Big Brands Poised To Lose US Marketing Exclusivity In 2019
Pink Sheet
AbbVie's 'Unjustified' Humira Settlements Divide Market, Class Action Claims
Scrip
Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019
Pink Sheet
Generic Sensipar: Cipla Challenges Legality of Amgen/Teva Patent Settlement
Pink Sheet
Launch Abbreviated: Teva Halts US Generic Sensipar Sales After Patent Deal With Amgen
Pink Sheet
Sensipar Generics: US Court Victory, FDA Approval Position Piramal For Launch
Pink Sheet
Pay-For-Delay Deals May Be Smaller After Supreme Court Okays FTC Suits

Topics

Related Companies

Advertisement
Tags:
Generic Drugs Launches Legal Issues
UsernamePublicRestriction

Register

PS124910

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By